VEGF

[World Journal of Surgical Oncology] The authors evaluate the relationship between VEGF and prognosis of intrahepatic cholangiocarcinoma by meta-analysis.

[Frontiers in Immunology] Using a human in vitro tri-culture system of macrophages with activated autologous T cells and BRAFV600E mutant melanoma cells, scientists showed that activated T cells and the synthetic triterpenoid the methyl CDDO-Me attenuated immune suppression.

[Molecular Biology Reports] Researchers assessed the suppressing effect of VGB4, a vascular endothelial growth factor (VEGF) antagonist peptide with the binding ability to both VEGF receptor1 and VEGF receptor2, on VEGF-induced proliferation and migration of the human lung adenocarcinoma cell line A549 and the human colon adenocarcinoma cell line HT29.

[Oncogene] Researchers reported that phenazine biosynthesis-like domain-containing protein (PBLD) inhibited hypoxia-induced angiogenesis via ERK/HIF-1a/VEGF axis in HCC cells.

[Cell and Tissue Research] In vitro functionality testing showed that these expanded cells promoted angiogenesis and, in brain glial cells, promoted cell proliferation and reduced production of reactive oxygen species during oxidative stress.

[Oncogene] Phenazine biosynthesis-like domain-containing protein (PBLD) exerted an inhibitory effect on angiogenesis not only via blocking the VEGFR2 expression in endothelial cells, but also through downregulating HIF-1a-induced VEGF expression and secretion in hepatocellular carcinoma cells.